Back

TOX enforces the immunosuppressive program of tumor-infiltrating regulatory T cells

Park, S.; Park, D. J.; Kim, M. J.; Kelly, G.; Zhang, R.; Kim, G.; Jeong, J.; Kim-Schulze, S.; Kim, H. R.; Kim, K.; Ha, S.-J.

2026-06-24 immunology
10.64898/2026.06.19.732838 bioRxiv
Show abstract

Regulatory T (Treg) cells accumulate in the tumor microenvironment (TME) to suppress anti-tumor immunity, but the transcriptional regulators stabilizing their immunosuppressive state remain poorly defined. Here we show that transcriptional factor TOX is selectively upregulated in tumor-infiltrating (TI) Treg cells across human cancers and mouse tumor models, while remaining low in peripheral and naive Treg populations. Treg-specific deletion of TOX reduced tumor burden, impaired TI Treg-mediated immune suppression, and enhanced effector functions of CD8 and CD4 T cells. In mosaic mice, TOX-deficient Tregs were selectively depleted from tumors, accompanied by increased apoptosis. Single-cell RNA sequencing and TCR clonotype analysis linked TOX expression to an effector-like TI Treg state with clonal expansion, whereas TOX loss shifted cells toward a TCF7-associated progenitor-like phenotype. ATAC-seq revealed enrichment of AP-1 motifs in TOX-sufficient TI Tregs. In contrast, TCF7, LEF1, and FOXO1 motifs in TOX-deficient counterparts, uncovering the opposing transcriptional networks downstream of TOX. Furthermore, TOX deficiency augmented CD8 T cell responses to PD-1 blockade. Together, these findings establish TOX as a key regulator of TI Treg fitness and stability, and identify it as a potential therapeutic target to enhance the efficacy of PD-1-based immunotherapy.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Communications
5641 papers in training set
Top 16%
11.7%
2
Nature Immunology
79 papers in training set
Top 0.2%
10.9%
3
Immunity
67 papers in training set
Top 0.1%
9.7%
4
Science Immunology
88 papers in training set
Top 0.2%
7.8%
5
Cell Reports
1498 papers in training set
Top 3%
7.8%
6
Cancer Cell
42 papers in training set
Top 0.2%
6.2%
50% of probability mass above
7
Journal of Experimental Medicine
119 papers in training set
Top 0.7%
3.4%
8
Cancer Immunology Research
35 papers in training set
Top 0.3%
3.4%
9
Science Advances
1243 papers in training set
Top 11%
3.2%
10
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.8%
2.7%
11
eLife
5828 papers in training set
Top 41%
2.4%
12
Journal of Clinical Investigation
179 papers in training set
Top 2%
2.4%
13
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 24%
2.1%
14
The EMBO Journal
309 papers in training set
Top 3%
2.1%
15
EMBO Reports
263 papers in training set
Top 3%
1.9%
16
Cancer Research
130 papers in training set
Top 2%
1.7%
17
Cell
431 papers in training set
Top 6%
1.7%
18
Nature
645 papers in training set
Top 7%
1.5%
19
JCI Insight
277 papers in training set
Top 5%
1.3%
20
Cancer Discovery
66 papers in training set
Top 1%
1.1%
21
Nucleic Acids Research
1281 papers in training set
Top 11%
1.1%
22
Science Translational Medicine
127 papers in training set
Top 3%
1.0%
23
Frontiers in Immunology
638 papers in training set
Top 10%
0.8%
24
EMBO Molecular Medicine
95 papers in training set
Top 3%
0.8%
25
Cell Reports Medicine
153 papers in training set
Top 5%
0.8%
26
Advanced Science
286 papers in training set
Top 11%
0.6%